Index of drugs

Treatment of non-infectious inflammatory diseases of the eyes that respond to corticosteroids, such as inflammation of the conjunctival and palpebral conjunctiva, cornea and anterior segment of the eyeball.

1 ml of suspension contains 1 mg of fluorometholone acetate.

Synthetic corticosteroid with strong anti-inflammatory properties in the form of ophthalmic preparation. When administered to the eye, fluorometholone acetate is well absorbed and distributed in the cornea and aqueous humor.

Hypersensitivity to the active substance or to any of the excipients. acute untreated bacterial infections. Herpetic keratitis. Krowianka, chickenpox and other viral infections of the cornea or conjunctiva. Fungal diseases of eye structures. Mycobacterium infections of the eye. Untreated purulent ocular infection. Corticosteroids should not be used in the presence of infections or wounds limited to the superficial corneal epithelium.

Long-term use of topical corticosteroid-containing eye medications may cause intraocular hypertension and / or glaucoma with damage to the optic nerve, visual acuity impairment, and visual field disorders, as well as the formation of posterior subcapsular cataract. Patients who require long-term use of ocular corticosteroids should routinely and frequently monitor intraocular pressure. This is particularly important in pediatric patients because the risk of corticosteroid-induced ocular hypertension may be higher in children and may occur more rapidly than in adults. The risk of developing ocular hypertension and cataract formation due to corticosteroids is higher in patients with other diseases (eg in patients with diabetes). Corticosteroids may reduce immunity and facilitate the development of resistant bacterial, fungal or viral infections and mask clinical signs of infection. Fungal infections should be suspected in patients with persistent corneal ulcer who received or receive these medications. Stop corticosteroid therapy if you have fungal infections. Topical corticosteroids may delay corneal healing. Topical NSAIDs can slow down and delay the healing process. The simultaneous use of NSAIDs with topically applied steroids may increase the risk of healing problems. In diseases occurring with corneal or scleral thinning, perforation was found due to the use of topical steroids. The use of contact lenses during the treatment of eye inflammation is not recommended. The preparation contains benzalkonium chloride, which may cause irritation and change the color of soft contact lenses. Avoid contact of drops with soft contact lenses. Patients who are allowed to use contact lenses must remove them before applying the preparation and keep at least 15 minutes from instillation of the drug to put on contact lenses. In patients with glaucoma, treatment with the preparation should be limited to 2 weeks, unless longer treatment is warranted. The intraocular pressure should be monitored. The local administration of corticosteroids may be accompanied by a reduction in cortisol secretion in urine as well as a decrease in plasma cortisol. A corticosteroid relationship has been observed with a decrease in the rate of growth in children, especially at high doses and long-term treatment. Patients who have been treated with systemic or topical corticosteroids for other diseases have had ophthalmic herpes. The use of corticosteroid therapy in the treatment of herpes, other than herpetic keratoconjunctivitis, in which it is contraindicated, requires great caution. Periodic microscopic examination in a slit lamp is necessary. Treatment should not be prematurely discontinued, as a rapid increase in inflammation may occur following sudden discontinuation of high doses of corticosteroids.

There are no data or data on the use of the preparation in pregnant women are limited.Studies of corticosteroid effects on animals have shown reproductive toxicity. A teratogenic and embryotoxic effect of fluorometholone in rabbits was found. The preparation should only be given to a pregnant woman when it is necessary. It is not known if fluorometholone or its metabolites are excreted in human milk after topical administration. Systemic corticosteroids are excreted in human milk. A risk to a breast-fed infant can not be excluded.

Uncommon: eye irritation, ocular hyperaemia, increased intraocular pressure. Rare: eye swelling, itchy eye, decreased visual acuity, subcapsular cataract, glaucoma, loss of visual field, mydriasis, eyelid drooping, impaired healing, eye infection (exacerbation or secondary infection), hypersensitivity reactions. Very rare: corneal perforation. Long-term topical application of corticosteroids to the eyes may cause increased intraocular pressure with damage to the optic nerve, decreased visual acuity and visual field disorders, as well as subcapsular cataract formation and delayed wound healing. When using a combination therapy with corticosteroids, secondary infections may occur. In the course of diseases leading to the thinning of the cornea or sclera, there is a higher risk of perforation.

Adolescents and adults, including the elderly: 1-2 drops into the conjunctival sac of the affected eye (sick eyes), 4 times a day. During the first 48 hours, the dosage may be increased by administering 2 drops every 2 hours. If no improvement occurs after 2 weeks of treatment, the patient should contact a physician. Regular monitoring of intraocular pressure is recommended. Premature discontinuation of treatment should be avoided. It is recommended to gently close the eyelid and compress the nasopharyngeal tract after instillation of the drug. If you use more than one eye medicine at the same time, you should keep at least 5 minutes between each medication. Eye Ointment should be used at the end. It is not recommended for use in children because safety and efficacy have not been established. The drug has not been tested in patients with impaired liver or kidney function. Shake the bottle before mixing to mix the suspension.